Table 4.
Association between NSAID use and atrial fibrillation in the three LHID combined dataset, grouped by defined daily dose (DDD) and cumulative prescriptions
| Controls | AF | Total | COR | 95% CI | AOR a | 95% CI | |
|---|---|---|---|---|---|---|---|
| Defined daily dose (DDD) | |||||||
| Non‐user | 9065 (31.77) | 7581 (26.57) | 16 646 | ||||
| DDD ≤ 0.5 | 9383 (32.89) | 10 980 (38.49) | 20 363 | 1.43 | 1.37–1.49 | 1.26 | 1.21–1.32 |
| 0.5 < DDD ≤ 1 | 7780 (27.27) | 7791 (27.31) | 15 571 | 1.23 | 1.17–1.29 | 1.11 | 1.06–1.17 |
| 1 < DDD | 2301 (8.07) | 2177 (7.63) | 4478 | 1.15 | 1.07–1.23 | 1.08 | 1.01–1.16 |
| Total | 28 529 | 28 529 | 57 058 | ||||
| Cumulative prescriptions | |||||||
| Non‐user | 9065 (31.77) | 7581 (26.57) | 16 646 | ||||
| 0 < prescriptions ≤ 2 | 7012 (24.58) | 7362 (25.81) | 14 374 | 1.28 | 1.22–1.33 | 1.19 | 1.14–1.25 |
| 2 < prescriptions ≤ 6 | 5925 (20.77) | 6236 (21.86) | 12 161 | 1.30 | 1.24–1.37 | 1.17 | 1.11–1.23 |
| 6 < prescriptions | 6527 (22.88) | 7350 (25.76) | 13 877 | 1.41 | 1.35–1.48 | 1.19 | 1.13–1.26 |
| Total | 28 529 | 28 529 | 57 058 | ||||
Adjusted variables included: medical comorbid disorders (CKD, MI, sleep apnoea, hyperthyroidism, ankylosing spondylitis, SLE, RA, gout, CAD and VHD), and concomitant medication use (antidepressants, anticonvulsants, anxiolytics, benzodiazepines, bisphosphonates, glucocorticosteroids and HRT).
AF, atrial fibrillation; AOR, adjusted odds ratio; CAD, coronary artery disease; CKD, chronic kidney disease; COR, crude odds ratio; HRT, hormone replacement therapy; LHID, Longitudinal Health Insurance Database; MI, myocardial infarction; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; VHD, valvular heart disease.